Drugs / human tetanus immunoglobulin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06302374 | Mar → Nov 2023 | tetanus | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | human tetanus immunoglobulin | “human tetanus immunoglobulin (HTIG)” NCT06302374 ↗ |
| Known as | HTIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06302374 ↗ |
| Modality | Protein / enzyme biologic | “human tetanus immunoglobulin (HTIG)” NCT06302374 ↗ |